Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy

The objective of this study was to investigate the predictive value of common genetic alterations of PI3K/AKT/mTOR and Ras/Raf/MAPK pathways in patients with locally advanced cervical squamous cell carcinoma (LACSCC) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). Patients with LAC...

Full description

Saved in:
Bibliographic Details
Published inExperimental and molecular pathology Vol. 98; no. 3; pp. 407 - 410
Main Authors Wang, Juan, Chai, Yan-lan, Wang, Tao, Liu, Jin-hui, Dai, Peng-gao, Liu, Zi
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.06.2015
Subjects
Antineoplastic Agents - therapeutic use
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - therapy
Cervical carcinoma
Chemoradiotherapy
Cisplatin - therapeutic use
Class I Phosphatidylinositol 3-Kinases
DNA Copy Number Variations
Female
Genetic alterations
Humans
Middle Aged
Mutation
Phosphatidylinositol 3-Kinases - genetics
PIK3CA
Response
Treatment Outcome
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - therapy
Response
Cervical carcinoma
PIK3CA
Chemoradiotherapy
Genetic alterations
Online AccessGet full text

Cover

Abstract The objective of this study was to investigate the predictive value of common genetic alterations of PI3K/AKT/mTOR and Ras/Raf/MAPK pathways in patients with locally advanced cervical squamous cell carcinoma (LACSCC) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). Patients with LACSCC, treated at a single institution with CCRT were eligible for this retrospective study. A total of sixty pre-treatment tumor biopsies were retrieved. Somatic mutations were detected by pyrosequencing and CNV was determined by quantitative realtime PCR. The association of genetic alterations with clinicopathological characteristics and treatment response were analyzed. Patients without genetic alterations (mutations or amplification) of PIK3CA had a significantly higher response rate than patients with these alterations (p=0.006). In the logistic regression analysis, PIK3CA genetic alterations retained an independent factor in predicting response to CCRT. Somatic mutations and copy number amplification of PIK3CA were associated with response to CCRT in patients with cervical squamous cell carcinoma.
AbstractList OBJECTIVEThe objective of this study was to investigate the predictive value of common genetic alterations of PI3K/AKT/mTOR and Ras/Raf/MAPK pathways in patients with locally advanced cervical squamous cell carcinoma (LACSCC) treated with cisplatin-based concurrent chemoradiotherapy (CCRT).METHODSPatients with LACSCC, treated at a single institution with CCRT were eligible for this retrospective study. A total of sixty pre-treatment tumor biopsies were retrieved. Somatic mutations were detected by pyrosequencing and CNV was determined by quantitative realtime PCR. The association of genetic alterations with clinicopathological characteristics and treatment response were analyzed.RESULTSPatients without genetic alterations (mutations or amplification) of PIK3CA had a significantly higher response rate than patients with these alterations (p=0.006). In the logistic regression analysis, PIK3CA genetic alterations retained an independent factor in predicting response to CCRT.CONCLUSIONSSomatic mutations and copy number amplification of PIK3CA were associated with response to CCRT in patients with cervical squamous cell carcinoma.
The objective of this study was to investigate the predictive value of common genetic alterations of PI3K/AKT/mTOR and Ras/Raf/MAPK pathways in patients with locally advanced cervical squamous cell carcinoma (LACSCC) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). Patients with LACSCC, treated at a single institution with CCRT were eligible for this retrospective study. A total of sixty pre-treatment tumor biopsies were retrieved. Somatic mutations were detected by pyrosequencing and CNV was determined by quantitative realtime PCR. The association of genetic alterations with clinicopathological characteristics and treatment response were analyzed. Patients without genetic alterations (mutations or amplification) of PIK3CA had a significantly higher response rate than patients with these alterations (p=0.006). In the logistic regression analysis, PIK3CA genetic alterations retained an independent factor in predicting response to CCRT. Somatic mutations and copy number amplification of PIK3CA were associated with response to CCRT in patients with cervical squamous cell carcinoma.
Author Liu, Zi
Liu, Jin-hui
Chai, Yan-lan
Wang, Tao
Wang, Juan
Dai, Peng-gao
Author_xml – sequence: 1
  givenname: Juan
  surname: Wang
  fullname: Wang, Juan
  organization: Department of Radiotherapy Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China
– sequence: 2
  givenname: Yan-lan
  surname: Chai
  fullname: Chai, Yan-lan
  organization: Department of Radiotherapy Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China
– sequence: 3
  givenname: Tao
  surname: Wang
  fullname: Wang, Tao
  organization: Department of Radiotherapy Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China
– sequence: 4
  givenname: Jin-hui
  surname: Liu
  fullname: Liu, Jin-hui
  organization: The National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi'an, PR China
– sequence: 5
  givenname: Peng-gao
  surname: Dai
  fullname: Dai, Peng-gao
  email: daipg@nwu.edu.cn
  organization: The National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi'an, PR China
– sequence: 6
  givenname: Zi
  surname: Liu
  fullname: Liu, Zi
  email: liuzmail@163.com
  organization: Department of Radiotherapy Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25773678$$D View this record in MEDLINE/PubMed
BookMark eNp9UcFu1DAUtFAR3Ra-AAn5yCWp7SROfOBQraBUrQSH9mx5nRetV4md2s6W_Sj-kbfdwpGTpfHMvDdvLsiZDx4I-chZyRmXV7vyAL-muRSMNyWrSsbrN2TFmZIFU3VzRlYMoaLuGDsnFyntGGOKcfGOnIumbSvZdivy-wY8ZGepGTNEk13wiYaB_ry9q9bX1Pie5mUKkUZIM_4BdZ7OyAOfE312eUvHYM04Hqjp98Zb6KmFuHeI0fS0mCksCZFxpNZE63yYDM0RTEbii9y6NI9o6IuNSUd18HaJEf2p3QKONr0LeYvLzYf35O1gxgQfXt9L8vjt68P6e3H_4-Z2fX1f2KpRuZCGtxhVKRiU4D0XrdrUojZMNbJpJBdN13SDkZ1QBkDabhAbW_NeDGwYKiGrS_L55DvH8LRAynpy6RjCeMA8msuOC8nQE6nViWpjSCnCoOfoJhMPmjN97Env9EtP-tiTZpXGUlD16XXAspmg_6f5WwwSvpwIgDH3DqJOFm-O53URbNZ9cP8d8Aff5ara
CitedBy_id crossref_primary_10_1042_BSR20191155
crossref_primary_10_1200_JCO_2015_65_7692
crossref_primary_10_1186_s12885_020_06779_4
crossref_primary_10_1002_hed_26891
crossref_primary_10_1007_s40615_021_01180_8
crossref_primary_10_1016_j_meegid_2018_08_001
crossref_primary_10_1016_j_ygyno_2017_10_009
crossref_primary_10_1097_GCO_0000000000000234
crossref_primary_10_1097_MD_0000000000011392
crossref_primary_10_1016_j_jbior_2015_10_009
crossref_primary_10_1159_000509095
crossref_primary_10_1016_j_ygyno_2020_06_506
crossref_primary_10_18632_oncotarget_18304
Cites_doi 10.1016/j.ygyno.2012.12.019
10.1002/cncr.28288
10.1053/clon.2002.0076
10.1093/jnci/92.3.205
10.1158/1078-0432.CCR-11-2485
10.1038/bjc.2011.222
10.1016/S1556-0864(15)31506-9
10.1016/S0020-7292(06)60030-1
10.1016/j.ygyno.2007.01.045
10.1586/erm.12.59
10.3322/caac.20107
10.1016/j.ygyno.2004.11.051
10.1016/j.ygyno.2005.09.029
10.1007/s10585-012-9483-3
10.1200/JCO.2008.16.4368
10.1158/1535-7163.MCT-10-0994
10.1016/j.ijrobp.2011.05.002
10.1111/j.1525-1438.2007.01111.x
10.1038/nrd1902
10.1016/S1470-2045(10)70130-3
10.1016/S0140-6736(01)05965-7
10.1016/S0140-6736(05)67625-8
10.1097/IGC.0b013e3182049924
10.1200/JCO.2011.36.1196
10.1371/journal.pone.0022769
10.1038/nature12881
10.1016/j.canlet.2007.11.004
ContentType Journal Article
Copyright 2015 Elsevier Inc.
Copyright © 2015 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2015 Elsevier Inc.
– notice: Copyright © 2015 Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.yexmp.2015.03.014
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1096-0945
EndPage 410
ExternalDocumentID 10_1016_j_yexmp_2015_03_014
25773678
S0014480015000490
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
-~X
.55
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29G
3O-
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXUO
ABBQC
ABFRF
ABGSF
ABJNI
ABLVK
ABMAC
ABMZM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
CS3
DM4
DOVZS
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
GROUPED_DOAJ
HDY
HLW
HMK
HMO
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
LCYCR
LG5
LX2
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SBG
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
UHS
UNMZH
WUQ
X7M
XPP
ZGI
ZMT
ZU3
~G-
0SF
AAXKI
ADVLN
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c359t-6a1709099ef921d1279b424a0956556125858fa6829aee6c8f2bc41d2f0ff3263
IEDL.DBID AIKHN
ISSN 0014-4800
IngestDate Fri Oct 25 21:52:58 EDT 2024
Thu Sep 26 15:53:00 EDT 2024
Sat Sep 28 08:06:20 EDT 2024
Fri Feb 23 02:30:56 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Response
Cervical carcinoma
PIK3CA
Chemoradiotherapy
Genetic alterations
Language English
License Copyright © 2015 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c359t-6a1709099ef921d1279b424a0956556125858fa6829aee6c8f2bc41d2f0ff3263
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25773678
PQID 1681260424
PQPubID 23479
PageCount 4
ParticipantIDs proquest_miscellaneous_1681260424
crossref_primary_10_1016_j_yexmp_2015_03_014
pubmed_primary_25773678
elsevier_sciencedirect_doi_10_1016_j_yexmp_2015_03_014
PublicationCentury 2000
PublicationDate June 2015
2015-Jun
2015-06-00
20150601
PublicationDateYYYYMMDD 2015-06-01
PublicationDate_xml – month: 06
  year: 2015
  text: June 2015
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Experimental and molecular pathology
PublicationTitleAlternate Exp Mol Pathol
PublicationYear 2015
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Pappa (bb0100) 2006; 100
Thatcher (bb0120) 2005; 366
Kang (bb0060) 2007; 105
Quinn (bb0105) 2006; 95
(bb0015) 2008; 26
Hennessy (bb0030) 2005; 4
Schwarz (bb0115) 2012; 18
Lee (bb0065) 2005; 97
Janku (bb0050) 2012; 30
Jemal (bb0055) 2011; 61
Miyake (bb0080) 2008; 261
Janku (bb0045) 2011; 10
Arias-Pulido (bb0005) 2008; 18
De Roock (bb0020) 2010; 11
Green (bb0025) 2001; 358
Lukka (bb0070) 2002; 14
Wegman (bb0130) 2011; 21
Janku (bb0040) 2011; 6
Therasse (bb0125) 2000; 92
Ojesina (bb0090) 2014; 506
Ong (bb0095) 2012; 12
McIntyre (bb0075) 2013; 128
Ryu (bb0110) 2011; 81
Iida (bb0035) 2011; 105
Molina, Adjei (bb0085) 2006; 1
Wright (bb0135) 2013; 119
Ashfaq (bb0010) 2012; 29
Lukka (10.1016/j.yexmp.2015.03.014_bb0070) 2002; 14
Therasse (10.1016/j.yexmp.2015.03.014_bb0125) 2000; 92
Iida (10.1016/j.yexmp.2015.03.014_bb0035) 2011; 105
Lee (10.1016/j.yexmp.2015.03.014_bb0065) 2005; 97
Quinn (10.1016/j.yexmp.2015.03.014_bb0105) 2006; 95
Jemal (10.1016/j.yexmp.2015.03.014_bb0055) 2011; 61
Hennessy (10.1016/j.yexmp.2015.03.014_bb0030) 2005; 4
Wright (10.1016/j.yexmp.2015.03.014_bb0135) 2013; 119
Pappa (10.1016/j.yexmp.2015.03.014_bb0100) 2006; 100
Miyake (10.1016/j.yexmp.2015.03.014_bb0080) 2008; 261
Molina (10.1016/j.yexmp.2015.03.014_bb0085) 2006; 1
Ong (10.1016/j.yexmp.2015.03.014_bb0095) 2012; 12
Janku (10.1016/j.yexmp.2015.03.014_bb0050) 2012; 30
Kang (10.1016/j.yexmp.2015.03.014_bb0060) 2007; 105
Thatcher (10.1016/j.yexmp.2015.03.014_bb0120) 2005; 366
Janku (10.1016/j.yexmp.2015.03.014_bb0040) 2011; 6
Green (10.1016/j.yexmp.2015.03.014_bb0025) 2001; 358
Wegman (10.1016/j.yexmp.2015.03.014_bb0130) 2011; 21
De Roock (10.1016/j.yexmp.2015.03.014_bb0020) 2010; 11
McIntyre (10.1016/j.yexmp.2015.03.014_bb0075) 2013; 128
Ryu (10.1016/j.yexmp.2015.03.014_bb0110) 2011; 81
Janku (10.1016/j.yexmp.2015.03.014_bb0045) 2011; 10
Ojesina (10.1016/j.yexmp.2015.03.014_bb0090) 2014; 506
Schwarz (10.1016/j.yexmp.2015.03.014_bb0115) 2012; 18
Ashfaq (10.1016/j.yexmp.2015.03.014_bb0010) 2012; 29
Arias-Pulido (10.1016/j.yexmp.2015.03.014_bb0005) 2008; 18
(10.1016/j.yexmp.2015.03.014_bb0015) 2008; 26
References_xml – volume: 95
  start-page: S43
  year: 2006
  end-page: S103
  ident: bb0105
  article-title: Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
  publication-title: Int. J. Gynaecol. Obstet.
  contributor:
    fullname: Quinn
– volume: 100
  start-page: 596
  year: 2006
  end-page: 600
  ident: bb0100
  article-title: Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status
  publication-title: Gynecol. Oncol.
  contributor:
    fullname: Pappa
– volume: 1
  start-page: 7
  year: 2006
  end-page: 9
  ident: bb0085
  article-title: The Ras/Raf/MAPK pathway
  publication-title: J. Thorac. Oncol.
  contributor:
    fullname: Adjei
– volume: 21
  start-page: 86
  year: 2011
  end-page: 91
  ident: bb0130
  article-title: Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy
  publication-title: Int. J. Gynecol. Cancer
  contributor:
    fullname: Wegman
– volume: 366
  start-page: 1527
  year: 2005
  end-page: 1537
  ident: bb0120
  article-title: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  publication-title: Lancet
  contributor:
    fullname: Thatcher
– volume: 30
  start-page: 777
  year: 2012
  end-page: 782
  ident: bb0050
  article-title: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Janku
– volume: 97
  start-page: 26
  year: 2005
  end-page: 34
  ident: bb0065
  article-title: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line
  publication-title: Gynecol. Oncol.
  contributor:
    fullname: Lee
– volume: 61
  start-page: 69
  year: 2011
  end-page: 90
  ident: bb0055
  article-title: Global cancer statistics
  publication-title: CA Cancer J. Clin.
  contributor:
    fullname: Jemal
– volume: 18
  start-page: 749
  year: 2008
  end-page: 754
  ident: bb0005
  article-title: Absence of epidermal growth factor receptor mutations in cervical cancer
  publication-title: Int. J. Gynecol. Cancer
  contributor:
    fullname: Arias-Pulido
– volume: 119
  start-page: 3776
  year: 2013
  end-page: 3783
  ident: bb0135
  article-title: Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix
  publication-title: Cancer
  contributor:
    fullname: Wright
– volume: 105
  start-page: 420
  year: 2011
  end-page: 427
  ident: bb0035
  article-title: EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
  publication-title: Br. J. Cancer
  contributor:
    fullname: Iida
– volume: 11
  start-page: 753
  year: 2010
  end-page: 762
  ident: bb0020
  article-title: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
  publication-title: Lancet Oncol.
  contributor:
    fullname: De Roock
– volume: 4
  start-page: 988
  year: 2005
  end-page: 1004
  ident: bb0030
  article-title: Exploiting the PI3K/AKT pathway for cancer drug discovery
  publication-title: Nat. Rev. Drug Discov.
  contributor:
    fullname: Hennessy
– volume: 14
  start-page: 203
  year: 2002
  end-page: 212
  ident: bb0070
  article-title: Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—a meta-analysis
  publication-title: Clin. Oncol. (R. Coll. Radiol.)
  contributor:
    fullname: Lukka
– volume: 10
  start-page: 558
  year: 2011
  end-page: 565
  ident: bb0045
  article-title: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
  publication-title: Mol. Cancer Ther.
  contributor:
    fullname: Janku
– volume: 261
  start-page: 120
  year: 2008
  end-page: 126
  ident: bb0080
  article-title: PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences
  publication-title: Cancer Lett.
  contributor:
    fullname: Miyake
– volume: 29
  start-page: 653
  year: 2012
  end-page: 655
  ident: bb0010
  article-title: Molecular profiling for personalized cancer care
  publication-title: Clin. Exp. Metastasis
  contributor:
    fullname: Ashfaq
– volume: 12
  start-page: 593
  year: 2012
  end-page: 602
  ident: bb0095
  article-title: Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing
  publication-title: Expert. Rev. Mol. Diagn.
  contributor:
    fullname: Ong
– volume: 81
  start-page: e577
  year: 2011
  end-page: e581
  ident: bb0110
  article-title: Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  contributor:
    fullname: Ryu
– volume: 92
  start-page: 205
  year: 2000
  end-page: 216
  ident: bb0125
  article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
  publication-title: J. Natl. Cancer Inst.
  contributor:
    fullname: Therasse
– volume: 128
  start-page: 409
  year: 2013
  end-page: 414
  ident: bb0075
  article-title: PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
  publication-title: Gynecol. Oncol.
  contributor:
    fullname: McIntyre
– volume: 18
  start-page: 1464
  year: 2012
  end-page: 1471
  ident: bb0115
  article-title: Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Schwarz
– volume: 358
  start-page: 781
  year: 2001
  end-page: 786
  ident: bb0025
  article-title: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis
  publication-title: Lancet
  contributor:
    fullname: Green
– volume: 105
  start-page: 662
  year: 2007
  end-page: 666
  ident: bb0060
  article-title: Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma
  publication-title: Gynecol. Oncol.
  contributor:
    fullname: Kang
– volume: 506
  start-page: 371
  year: 2014
  end-page: 375
  ident: bb0090
  article-title: Landscape of genomic alterations in cervical carcinomas
  publication-title: Nature
  contributor:
    fullname: Ojesina
– volume: 26
  start-page: 5802
  year: 2008
  end-page: 5812
  ident: bb0015
  article-title: Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials
  publication-title: J. Clin. Oncol.
– volume: 6
  start-page: e22769
  year: 2011
  ident: bb0040
  article-title: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
  publication-title: PLoS One
  contributor:
    fullname: Janku
– volume: 128
  start-page: 409
  year: 2013
  ident: 10.1016/j.yexmp.2015.03.014_bb0075
  article-title: PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2012.12.019
  contributor:
    fullname: McIntyre
– volume: 119
  start-page: 3776
  year: 2013
  ident: 10.1016/j.yexmp.2015.03.014_bb0135
  article-title: Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix
  publication-title: Cancer
  doi: 10.1002/cncr.28288
  contributor:
    fullname: Wright
– volume: 14
  start-page: 203
  year: 2002
  ident: 10.1016/j.yexmp.2015.03.014_bb0070
  article-title: Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—a meta-analysis
  publication-title: Clin. Oncol. (R. Coll. Radiol.)
  doi: 10.1053/clon.2002.0076
  contributor:
    fullname: Lukka
– volume: 92
  start-page: 205
  year: 2000
  ident: 10.1016/j.yexmp.2015.03.014_bb0125
  article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/92.3.205
  contributor:
    fullname: Therasse
– volume: 18
  start-page: 1464
  year: 2012
  ident: 10.1016/j.yexmp.2015.03.014_bb0115
  article-title: Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-2485
  contributor:
    fullname: Schwarz
– volume: 105
  start-page: 420
  year: 2011
  ident: 10.1016/j.yexmp.2015.03.014_bb0035
  article-title: EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2011.222
  contributor:
    fullname: Iida
– volume: 1
  start-page: 7
  year: 2006
  ident: 10.1016/j.yexmp.2015.03.014_bb0085
  article-title: The Ras/Raf/MAPK pathway
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/S1556-0864(15)31506-9
  contributor:
    fullname: Molina
– volume: 95
  start-page: S43
  issue: Suppl. 1
  year: 2006
  ident: 10.1016/j.yexmp.2015.03.014_bb0105
  article-title: Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
  publication-title: Int. J. Gynaecol. Obstet.
  doi: 10.1016/S0020-7292(06)60030-1
  contributor:
    fullname: Quinn
– volume: 105
  start-page: 662
  year: 2007
  ident: 10.1016/j.yexmp.2015.03.014_bb0060
  article-title: Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2007.01.045
  contributor:
    fullname: Kang
– volume: 12
  start-page: 593
  year: 2012
  ident: 10.1016/j.yexmp.2015.03.014_bb0095
  article-title: Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing
  publication-title: Expert. Rev. Mol. Diagn.
  doi: 10.1586/erm.12.59
  contributor:
    fullname: Ong
– volume: 61
  start-page: 69
  year: 2011
  ident: 10.1016/j.yexmp.2015.03.014_bb0055
  article-title: Global cancer statistics
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.20107
  contributor:
    fullname: Jemal
– volume: 97
  start-page: 26
  year: 2005
  ident: 10.1016/j.yexmp.2015.03.014_bb0065
  article-title: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2004.11.051
  contributor:
    fullname: Lee
– volume: 100
  start-page: 596
  year: 2006
  ident: 10.1016/j.yexmp.2015.03.014_bb0100
  article-title: Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2005.09.029
  contributor:
    fullname: Pappa
– volume: 29
  start-page: 653
  year: 2012
  ident: 10.1016/j.yexmp.2015.03.014_bb0010
  article-title: Molecular profiling for personalized cancer care
  publication-title: Clin. Exp. Metastasis
  doi: 10.1007/s10585-012-9483-3
  contributor:
    fullname: Ashfaq
– volume: 26
  start-page: 5802
  year: 2008
  ident: 10.1016/j.yexmp.2015.03.014_bb0015
  article-title: Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.16.4368
– volume: 10
  start-page: 558
  year: 2011
  ident: 10.1016/j.yexmp.2015.03.014_bb0045
  article-title: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-10-0994
  contributor:
    fullname: Janku
– volume: 81
  start-page: e577
  year: 2011
  ident: 10.1016/j.yexmp.2015.03.014_bb0110
  article-title: Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/j.ijrobp.2011.05.002
  contributor:
    fullname: Ryu
– volume: 18
  start-page: 749
  year: 2008
  ident: 10.1016/j.yexmp.2015.03.014_bb0005
  article-title: Absence of epidermal growth factor receptor mutations in cervical cancer
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1111/j.1525-1438.2007.01111.x
  contributor:
    fullname: Arias-Pulido
– volume: 4
  start-page: 988
  year: 2005
  ident: 10.1016/j.yexmp.2015.03.014_bb0030
  article-title: Exploiting the PI3K/AKT pathway for cancer drug discovery
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd1902
  contributor:
    fullname: Hennessy
– volume: 11
  start-page: 753
  year: 2010
  ident: 10.1016/j.yexmp.2015.03.014_bb0020
  article-title: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(10)70130-3
  contributor:
    fullname: De Roock
– volume: 358
  start-page: 781
  year: 2001
  ident: 10.1016/j.yexmp.2015.03.014_bb0025
  article-title: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(01)05965-7
  contributor:
    fullname: Green
– volume: 366
  start-page: 1527
  year: 2005
  ident: 10.1016/j.yexmp.2015.03.014_bb0120
  article-title: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67625-8
  contributor:
    fullname: Thatcher
– volume: 21
  start-page: 86
  year: 2011
  ident: 10.1016/j.yexmp.2015.03.014_bb0130
  article-title: Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1097/IGC.0b013e3182049924
  contributor:
    fullname: Wegman
– volume: 30
  start-page: 777
  year: 2012
  ident: 10.1016/j.yexmp.2015.03.014_bb0050
  article-title: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.36.1196
  contributor:
    fullname: Janku
– volume: 6
  start-page: e22769
  year: 2011
  ident: 10.1016/j.yexmp.2015.03.014_bb0040
  article-title: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0022769
  contributor:
    fullname: Janku
– volume: 506
  start-page: 371
  year: 2014
  ident: 10.1016/j.yexmp.2015.03.014_bb0090
  article-title: Landscape of genomic alterations in cervical carcinomas
  publication-title: Nature
  doi: 10.1038/nature12881
  contributor:
    fullname: Ojesina
– volume: 261
  start-page: 120
  year: 2008
  ident: 10.1016/j.yexmp.2015.03.014_bb0080
  article-title: PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2007.11.004
  contributor:
    fullname: Miyake
SSID ssj0009012
Score 2.1970093
Snippet The objective of this study was to investigate the predictive value of common genetic alterations of PI3K/AKT/mTOR and Ras/Raf/MAPK pathways in patients with...
OBJECTIVEThe objective of this study was to investigate the predictive value of common genetic alterations of PI3K/AKT/mTOR and Ras/Raf/MAPK pathways in...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 407
SubjectTerms Antineoplastic Agents - therapeutic use
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - therapy
Cervical carcinoma
Chemoradiotherapy
Cisplatin - therapeutic use
Class I Phosphatidylinositol 3-Kinases
DNA Copy Number Variations
Female
Genetic alterations
Humans
Middle Aged
Mutation
Phosphatidylinositol 3-Kinases - genetics
PIK3CA
Response
Treatment Outcome
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - therapy
Title Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy
URI https://dx.doi.org/10.1016/j.yexmp.2015.03.014
https://www.ncbi.nlm.nih.gov/pubmed/25773678
https://search.proquest.com/docview/1681260424
Volume 98
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9QwDLZ2ZyXggmB5DY9VkDgSdtKmaXMcjVjNMtoVQqzYW5Q2qdQVkw7zkJgL_4j_iJ22IA7LgVPVKlYj27Id2_kM8EYrl-Y-V7wq84RLpTJeCFHyvHBJraXz3lJq4OJSza_kh-vs-gBmw10YaqvsbX9n06O17r-c9tw8XTUN3fHFw0ARMfJi_eoQjtAdJcUIjqbni_nlH-zdiehAw4XkRDCAD8U2r73_viTcSpFFsFMhb3NQtwWg0RGdPYD7fQTJpt0mH8KBD8dwdzYMbjuGOxd9vfwR_CRUaVzHYlG8S86xtmYfzxfpbMpscGy7W7Zrtu5aZT1rAuuhVjeMcrQsOruvezY0C7AqWhfcwebbzlLigFHyn1U0lCi0S8ti7zoujORVs1lRu13g5C-Rug1VBwnFUF3w19Y1_SWw_WO4Onv_eTbn_YAGXqWZ3nJlRY7c1drXOhFOJLkuZSItgRvGsZt4Filqq4pEW-9VVdRJWUmBWjCpa4wb0ycwCm3wz4BJjwdB6VTpXClljWGlyMoM6UtbOKH1GN4OUjGrDofDDA1qNyYK0ZAQzSQ1KMQxqEFy5i91Mugp_k34epCzQbERA23wyEsjCKlNUaV4DE87Bfi9E7R7eYpu__n__vYF3KO3rgftJYy2651_hdHOtjyBw3c_xEmv0_RcfPqy-AWZuALY
link.rule.ids 315,783,787,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKK1EuCAqUBQpG4ojVdeI48XG1otrtdlccWqk3y44dKYh1tvuQuj-q_5HxIyAO5cA1ycjWzGRmPDP-BqEvgpu8tCUntS4zwjgvSEWpJmVlskYwY63yqYH5gk9u2OVtcXuAxv1dGN9WmWx_tOnBWqcn54mb56u29Xd84TBQBYy8UL96go4gGhDwdx6NprPJ4g_27pBG0HDKiCfowYdCm9fe3i89biUtAtgpZY85qMcC0OCILl6g5ymCxKO4yZfowLoTdDzuB7edoKfzVC9_hR48qjR8h0NRPCbncNfg79NZPh5h5Qze7pbdGq9jq6zFrcMJanWDfY4WB2f3c4_7ZgFcB-sCO9jc7ZRPHGCf_Me1H0rkuqXCoXcdPgzkdbtZ-XY7R7y_BOrO1RESCoO6wNLKtOkS2P41urn4dj2ekDSggdR5IbaEK1oCd4WwjciooVkpNMuY8uCGYewmnEWqRvEqE8paXldNpmtGQQuGTQNxY_4GHbrO2bcIMwsHQWa4NkYz1kBYSQtdAL1WlaFCDNDXXipyFXE4ZN-g9kMGIUovRDnMJQhxgHgvOfmXOknwFP8m_NzLWYLYPAOVs8BLST1SG_eV4gE6jQrweydg98oc3P67_132EzqeXM-v5NV0MXuPnvk3sR_tAzrcrnf2DCKfrf6YNPsXwfMDKQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+alterations+of+PIK3CA+and+tumor+response+in+patients+with+locally+advanced+cervical+squamous+cell+carcinoma+treated+with+cisplatin-based+concurrent+chemoradiotherapy&rft.jtitle=Experimental+and+molecular+pathology&rft.au=Wang%2C+Juan&rft.au=Chai%2C+Yan-lan&rft.au=Wang%2C+Tao&rft.au=Liu%2C+Jin-hui&rft.date=2015-06-01&rft.eissn=1096-0945&rft.volume=98&rft.issue=3&rft.spage=407&rft.epage=410&rft_id=info:doi/10.1016%2Fj.yexmp.2015.03.014&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-4800&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-4800&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-4800&client=summon